70%小鼠消除胰腺癌！华人专家处理“癌症之王”新办法登上《细胞》
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">常被<span style="color: black;">叫作</span>为“癌症之王”的胰腺导管腺癌（pancreatic ductal adenocarcinoma，PDAC），是胰腺癌中最<span style="color: black;">平常</span>的类型，<span style="color: black;">亦</span>是各类实体瘤中最为凶险的癌症之一。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在其他<span style="color: black;">非常多</span>癌症中取得良好效果的化疗、免疫疗法等，遇到胰腺导管腺癌<span style="color: black;">常常</span><span style="color: black;">没</span>力回天。<span style="color: black;">日前</span>转移性胰腺癌的标准治疗为化疗组合，客观缓解率<span style="color: black;">仅有</span>23%<span style="color: black;">上下</span>。<span style="color: black;">有些</span>临床<span style="color: black;">实验</span><span style="color: black;">表示</span>，在化疗<span style="color: black;">基本</span>上添加免疫疗法，如PD-1<span style="color: black;">控制</span>剂，<span style="color: black;">亦</span><span style="color: black;">无</span><span style="color: black;">供给</span>额外获益。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">然而，日前顶尖学术期刊《细胞》上<span style="color: black;">发布</span>了一项令人振奋的<span style="color: black;">科研</span>，有望改变胰腺癌治疗困难的局面。</p>
<div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic2.zhimg.com/80/v2-a3ae35e6514f7676d5ddeab6cd8983b5_720w.jpg" style="width: 50%; margin-bottom: 20px;"></div>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">领衔这项<span style="color: black;">科研</span>的是哈佛医学院华人<span style="color: black;">专家</span>卢坤平教授和周小珍教授。两位<span style="color: black;">专家</span>在过去<span style="color: black;">数年</span>的合作中，围绕一种独特的脯氨酸异构酶Pin1进行了<span style="color: black;">仔细</span><span style="color: black;">科研</span>。这种酶<span style="color: black;">经过</span>影响其他蛋白的结构和磷酸化，调节<span style="color: black;">非常多</span>与细胞周期<span style="color: black;">相关</span>的<span style="color: black;">要紧</span>蛋白，其信号传导的失调对多种癌症以及阿尔茨海默病的发展产生影响。</p>
<div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic1.zhimg.com/80/v2-dc41b94ed67b5b4bbf1192e78b0ff5ec_720w.jpg" style="width: 50%; margin-bottom: 20px;"></div>▲<span style="color: black;">科研</span>通讯作者卢坤平教授和周小珍教授（<span style="color: black;">照片</span><span style="color: black;">源自</span>：<span style="color: black;">科研</span>者所在<span style="color: black;">公司</span>官网）<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">此次<span style="color: black;">科研</span>中，这支团队<span style="color: black;">发掘</span>，Pin1在胰腺导管腺癌<span style="color: black;">病人</span>的癌细胞和癌症<span style="color: black;">关联</span>成纤维细胞中都有过量表达，并且Pin1高表达与<span style="color: black;">病人</span>的不良<span style="color: black;">存活</span>率<span style="color: black;">关联</span>。<span style="color: black;">因此呢</span>，<span style="color: black;">科研</span>人员探索了靶向<span style="color: black;">控制</span>Pin1治疗胰腺癌的可能性。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">实验结果<span style="color: black;">表示</span>，在多种胰腺癌模型小鼠中，<span style="color: black;">运用</span>临床上已<span style="color: black;">研发</span>的Pin1<span style="color: black;">控制</span>剂，与免疫疗法PD-1<span style="color: black;">控制</span>剂、化疗<span style="color: black;">药品</span>吉西他滨（gemcitabine）协同<span style="color: black;">功效</span>，<span style="color: black;">能够</span>完全消除或<span style="color: black;">连续</span>缓解小鼠<span style="color: black;">身体</span>的肿瘤！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在引入两种致癌基因Kras和p53突变的胰腺癌小鼠中，<span style="color: black;">倘若</span>仅用吉西他滨和PD-1<span style="color: black;">控制</span>剂治疗，效果甚微，大部分小鼠在3个月内死亡；然而，加入Pin1<span style="color: black;">控制</span>剂的治疗<span style="color: black;">明显</span><span style="color: black;">加强</span>了<span style="color: black;">存活</span>率，70%的小鼠在治疗后<span style="color: black;">最少</span>存活6个月，并且<span style="color: black;">身体</span>的肿瘤消失了。</p>
<div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic4.zhimg.com/80/v2-0bc8dff5582fb12bfc596e07a2553a53_720w.webp" style="width: 50%; margin-bottom: 20px;"></div>▲Pin1<span style="color: black;">控制</span>剂与免疫疗法、化疗联手根除胰腺癌的示意图（<span style="color: black;">照片</span><span style="color: black;">源自</span>：参考资料）<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">针对</span>Pin1<span style="color: black;">控制</span>剂<span style="color: black;">为么</span>能<span style="color: black;">明显</span><span style="color: black;">加强</span>免疫化疗的效果，<span style="color: black;">科研</span>小组<span style="color: black;">亦</span>对<span style="color: black;">暗地里</span>的机制进行了分析。<span style="color: black;">她们</span><span style="color: black;">发掘</span>，靶向Pin1<span style="color: black;">能够</span><span style="color: black;">同期</span>阻断多条癌症信号通路，并且<span style="color: black;">经过</span><span style="color: black;">功效</span>于癌症<span style="color: black;">关联</span>成纤维细胞，解除肿瘤微环境的免疫<span style="color: black;">控制</span>性；<span style="color: black;">另外</span>，靶向Pin1还<span style="color: black;">能够</span>诱导癌细胞多表达PD-1配体PD-L1，以及细胞摄取吉西他滨的转运蛋白ENT1，让癌细胞<span style="color: black;">更易</span>被PD-1<span style="color: black;">控制</span>剂和吉西他滨彻底铲除。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">咱们</span>期待这一潜在治疗策略<span style="color: black;">能够</span>在后续的临床<span style="color: black;">实验</span>中取得顺利结果，<span style="color: black;">早点</span>造福胰腺癌<span style="color: black;">病人</span>。</p>
<div style="color: black; text-align: left; margin-bottom: 10px;">参考资料
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. Doi: https://doi.org/10.1016/j.cell.2021.07.020</div>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">▎药明康德内容团队编辑</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">注：本文旨在介绍医药健康<span style="color: black;">科研</span><span style="color: black;">发展</span>，不是治疗<span style="color: black;">方法</span><span style="color: black;">举荐</span>。如需<span style="color: black;">得到</span>治疗<span style="color: black;">方法</span><span style="color: black;">指点</span>，请前往正规医院就诊。欢迎个人转发至<span style="color: black;">伴侣</span>圈，谢绝<span style="color: black;">媒介</span>或<span style="color: black;">公司</span>未经授权以任何形式转载至其他平台。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">⤵️<span style="color: black;">爱好</span><span style="color: black;">咱们</span>的内容，欢迎关注</p>
<div style="color: black; text-align: left; margin-bottom: 10px;"><a style="color: black;">@药明康德</a></div>！<span style="color: black;">或</span>点赞、评论、分享给其他读者吧！
页:
[1]